ChromaDex’s research and development program
reaches over 250 material transfer agreements (MTAs) on Niagen® and
other ingredients, marking a milestone in NAD+ research
ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material
transfer agreements (MTAs) through the ChromaDex External Research
Program (CERP™), featuring ChromaDex’s flagship ingredient Niagen®
(patented nicotinamide riboside, or NR) and other proprietary
ingredients. Over 235 independent scientists, doctors, and
investigators across 182 institutions and 33 countries developed
the 250+ MTAs to further research using various ChromaDex
materials. Many of the agreements were developed to study Niagen,
ChromaDex’s proprietary nicotinamide riboside (NR) ingredient, an
efficient precursor for the essential cellular coenzyme,
nicotinamide adenine dinucleotide (NAD+). ChromaDex has donated
over $1.94 million in NR to date to further research around NR and
NAD+. As of April 2022, 102 peer-reviewed published preclinical and
clinical studies have resulted from these MTAs, furthering
ChromaDex as a leader in NAD+ and healthy aging research.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220414005182/en/
ChromaDex Celebrates over 250 Material
Transfer Agreements (MTAs) (Graphic: Business Wire)
“We are thrilled to celebrate over 250 MTAs, as this achievement
reinforces our dedication to leading the industry in the science of
NAD+ and NR,” said Dr. Andrew Shao, ChromaDex Senior Vice President
of Global Regulatory and Scientific Affairs. “We believe the
research being done through CERP is making a positive difference
and will help communities throughout the world.”
ChromaDex’s MTA program was established in 2013 by Founder and
Chairman of the Board, Frank Jaksch, to advance the science of NR
as a novel NAD+ precursor and other ChromaDex materials. In 2019,
the program was branded as the ChromaDex External Research Program
(CERP). Through the program’s evolution, ChromaDex not only
provides materials (bulk, clinical, and matching placebo), in kind,
for outstanding research proposals, but a group of
interdisciplinary scientists also supports the technical and
intellectual property needs of investigators, presents research at
conferences, and is helping to build and support the NAD+ and
healthy aging research community. The results of the 250+ research
agreements have allowed CERP to help produce the trusted science
behind Niagen and continue to advance the understanding of NAD+ in
health, diseases, and aging.
“CERP is an important component of ChromaDex’s philanthropy. Our
internal multidisciplinary and cross-functional scientists are not
only providing high-quality material for research, but also
creating community and multidimensional support for the
investigators in our program,” said Dr. Yasmeen Nkrumah-Elie,
Global Director of Research and Development for External Research
at ChromaDex. “Our goal is to set the standard for excellence in
industry-academic relationships and collaborations, and the metrics
from our program are demonstrating that we are achieving this
goal.”
The research conducted by CERP investigators has supported the
advancement of science in important age-related health areas such
as cellular health, cellular energy, heart health, muscle health,
and brain health. Notable clinical publications from the CERP
investigators include:
- Elhassan et al. 2019 demonstrated that oral nicotinamide
riboside increases the NAD+ metabolome and was found to reduce the
levels of circulating inflammatory cytokines.
- Zhou et al. 2020 demonstrated that nicotinamide riboside
supplementation reduced signs of inflammation, specifically
inflammatory cytokines, in an open-label pilot study of a small
group of end-stage heart failure patients. A second arm of the
study, conducted ex vivo, found nicotinamide riboside improved
mitochondrial respiration and augmented inflammatory response in
primary cells isolated from human subjects.
- Brakedal et al. 2022 utilized Niagen to increase cerebral NAD+
levels, which resulted in altered cerebral energy metabolism,
decreased levels of inflammatory cytokines, and improved symptoms
in patients with Parkinson’s disease. As seen in the peer-reviewed
Cell Metabolism study.
“By providing us with NR (Niagen), the CERP team has made an
essential contribution to the NADPARK study, a first of its kind
phase I clinical trial of NR therapy in Parkinson’s disease,” said
Prof. Charalampos Tzoulis, Professor of Neurology and
Neurogenetics, Director of the K.G Jebsen Center for Translational
Research in Parkinson’s disease, and Co-Director of the
Neuro-SysMed Research Center, University of Bergen and Haukeland
University Hospital, Bergen, Norway. “The results of the trial are
highly encouraging and nominate NR as a potential neuroprotective
therapy for PD. Moreover, we believe the ability to augment brain
NAD+ levels using NR now opens new potential avenues for the
treatment of neurological diseases. Multiple new phase II trials
have been initiated at our Center with the CERP team’s valuable
contribution of the NR and placebo material required for the
studies.”
“The CERP program is an invaluable platform that allows
investigators, such as myself, to lead the critical research behind
NR. CERP has helped disseminate safety-tested NR globally and
allowed myself and others to extend the boundaries of what is known
about NR and NAD+ metabolism,” said Dr. Charles Brenner, Alfred E
Mann Family Foundation Chair in Diabetes and Cancer Metabolism at
City of Hope National Medical Center and ChromaDex Chief Scientific
Advisor. “These 250+ MTAs are a testament to ChromaDex’s dedication
to shepherding the industry forward and helping to elevate the
lives of people throughout the world.”
For additional information on the science supporting Niagen
visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements related to results of the NIAGEN® studies,
their significance and whether the studies show potential for
benefits on human health and specifically whether NR has the
ability to augment brain NAD+ levels opening new avenues for the
treatment of neurological diseases. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. Other risks that contribute to the
uncertain nature of the forward-looking statements include:
unfavorable publicity or changing consumer perceptions of our
products; our inability to commercialize further products; reliance
on a single or limited number of third-party suppliers for raw
materials to produce our products; and the risks and uncertainties
associated with our business and financial condition in general,
described in ChromaDex's Annual Report on Form 10-K for the fiscal
year ended December 31, 2021, ChromaDex's Quarterly Reports on Form
10-Q and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220414005182/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024